ライフサイエンスコーパス: head and neck squamous cell carcinoma

1 referably point to CHCT/MRI in patients with head and neck squamous cell carcinoma.

2 Mediterranean Diet Score (aMED)] and risk of head and neck squamous cell carcinoma.

3 r the start of radiotherapy in patients with head and neck squamous cell carcinoma.

4 not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma.

5 vival (HR, 3.98; P = 0.001) in patients with head and neck squamous cell carcinoma.

6 genesis in multiple human cancers, including head and neck squamous cell carcinoma.

7 and growth in non-small cell lung cancer and head and neck squamous cell carcinoma.

8 ost commonly used agents in the treatment of head and neck squamous cell carcinoma.

9 been undertaken to improve classification of head and neck squamous cell carcinoma.

10 -L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma.

11 us new understanding of the pathogenesis of head and neck squamous cell carcinoma.

12 ng concurrent chemoradiotherapy for advanced head and neck squamous cell carcinoma.

13 g metabolic and malignant phenotype in human head and neck squamous cell carcinoma.

14 rrelates with poor prognosis in melanoma and head and neck squamous cell carcinoma.

15 is down-regulated in glioblastoma cells and head and neck squamous cell carcinoma.

16 ut with lost or down-regulated expression in head and neck squamous cell carcinoma.

17 in patient survival of five cancers, such as head and neck squamous cell carcinoma.

18 d with esophageal squamous cell carcinoma or head and neck squamous cell carcinoma.

19 urine models of melanoma, neuroblastoma, and head and neck squamous cell carcinoma.

20 oor outcome in an independent data set of 71 head and neck squamous cell carcinomas.

21 s, other anogenital cancers, and a subset of head and neck squamous cell carcinomas.

22 agents of a subset of anogenital cancers and head and neck squamous cell carcinomas.

23 quenced the whole mitochondrial genome in 83 head and neck squamous cell carcinomas.

24 ositol 3-kinase (PI3Kalpha), are frequent in head and neck squamous cell carcinomas.

25 ting dose-limiting toxicity in patients with head and neck squamous cell carcinomas.

26 cted after antiangiogenic therapy, except in head and neck squamous cell carcinoma 19 d after the sta

27 The most frequent solid tumors were head and neck squamous cell carcinomas (40% of patients

28 approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic col

29 powerful immunotherapeutic tool to eradicate head and neck squamous cell carcinoma and other poorly i

30 ALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently

31 y methylated and silenced in the majority of head and neck squamous cell carcinomas and non-small-cel

32 uding non-small cell lung carcinoma (NSCLC), head and neck squamous cell carcinoma, and ovarian cance

33 o different cancer cell lines, FaDu, a human head and neck squamous cell carcinoma, and RKO, a human

34 and management of HPV-related oropharyngeal head and neck squamous cell carcinoma, and to describe u

35 cer, multiple myeloma, neuroendocrine tumor, head and neck squamous cell carcinoma, and unknown prima

36 at the gene is mutated in 6% of GBMs, 13% of head and neck squamous cell carcinomas, and in 9% of lun

37 26 with non-small-cell lung cancer, 55 with head and neck squamous-cell carcinoma, and 55 with gastr

38 ng cancer, four (9%, 2-21) of 45 people with head and neck squamous-cell carcinoma, and four (9%, 2-2

39 greater enrichment of previously identified head and neck squamous cell carcinoma associated gene se

40 derwent upfront nodal dissection for mucosal head and neck squamous cell carcinoma between 2004 and 2

41 rlotinib are currently used in patients with head and neck squamous cell carcinoma, but, in this dise

42 c bioconjugate was examined in the HN5 human head and neck squamous cell carcinoma cell line.

43 pithelial cell lines, was present in several head and neck squamous cell carcinoma cell lines and was

44 ing radiation and delays the growth of human head and neck squamous cell carcinoma cell lines in 3D c

45 PpFur expression in head and neck squamous cell carcinoma cell lines showed

46 nts described here compared the responses of head and neck squamous cell carcinoma cell lines to two

47 Transfection of four human head and neck squamous cell carcinoma cell lines with th

48 mote cancer stem cell-like properties in two head and neck squamous cell carcinoma cell lines, UMSCC-

49 correlates with loss of CXCL14 secretion by head and neck squamous cell carcinoma cell lines, wherea

50 and induced apoptosis in FaDu and Cal27, two head and neck squamous cell carcinoma cell lines.

51 Head and neck squamous cell carcinoma cells exposed to c

52 The selective action of MT-DADMe-ImmA on head and neck squamous cell carcinoma cells suggests pot

53 s were tested against naturally HPV-infected head and neck squamous cell carcinoma cells using IFN-ga

54 he molecular effects of SCH66336, an FTI, in head and neck squamous cell carcinoma cells using proteo

55 and undergoes caspase-dependent cleavage in head and neck squamous cell carcinoma cells.

56 epidemic of human papillomavirus-associated head and neck squamous cell carcinomas characterized by

57 In this study, we determined that human head and neck squamous cell carcinoma-derived HSC-3 cell

58 r, other anogenital cancers, and a subset of head and neck squamous cell carcinomas, encode three onc

59 n of NANOG in cell lines from oesophageal or head and neck squamous cell carcinomas (ESCCs or HNSCCs,

60 Critically, in head and neck squamous cell carcinoma, Fxr1 overexpressi

61 idence of human papillomavirus (HPV)-related head and neck squamous cell carcinoma has increased in r

62 cancers, including chronic myeloid leukemia, head and neck squamous cell carcinoma, hepatocellular ca

63 are putative tumor-initiating cells (TIC) in head and neck squamous cell carcinomas (HNC).

64 nsferase NSD1 define an intrinsic subtype of head and neck squamous cell carcinoma (HNSC) that featur

65 Head and neck squamous cell carcinoma (HNSCC) accounts f

66 ng chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 non

67 diotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomar

68 ear survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and curren

69 EphB4 receptor is ubiquitously expressed in head and neck squamous cell carcinoma (HNSCC) and has be

70 Head and neck squamous cell carcinoma (HNSCC) and many o

71 Given the potential relationship between head and neck squamous cell carcinoma (HNSCC) and microb

72 mechanism strongly inhibited cell growth in head and neck squamous cell carcinoma (HNSCC) and non-sm

73 channel that is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) and other

74 DNA amplification is frequently observed in head and neck squamous cell carcinoma (HNSCC) and potent

75 The majority of head and neck squamous cell carcinoma (HNSCC) and some c

76 We investigated how frequent this occurs in head and neck squamous cell carcinoma (HNSCC) and whethe

77 Patients with head and neck squamous cell carcinoma (HNSCC) are at ele

78 rates of local recurrence in tobacco-related head and neck squamous cell carcinoma (HNSCC) are common

79 The prototypic head and neck squamous cell carcinoma (HNSCC) arises fro

80 ur purpose was to examine whether staging of head and neck squamous cell carcinoma (HNSCC) by upfront

81 Head and neck squamous cell carcinoma (HNSCC) can be div

82 Human papillomavirus-negative head and neck squamous cell carcinoma (HNSCC) carries a

83 iously shown that some gefitinib-insensitive head and neck squamous cell carcinoma (HNSCC) cell lines

84 89) inhibits cell cycle progression of human head and neck squamous cell carcinoma (HNSCC) cell lines

85 We screened a panel of 49 established human head and neck squamous cell carcinoma (HNSCC) cell lines

86 NOK strains (n = 8), dysplasias (n = 5) and head and neck squamous cell carcinoma (HNSCC) cell lines

87 Our work shows that head and neck squamous cell carcinoma (HNSCC) cell lines

88 DeltaNp63alpha in the nucleus of a subset of head and neck squamous cell carcinoma (HNSCC) cell lines

89 elial growth factor (VEGF) autocrine loop in head and neck squamous cell carcinoma (HNSCC) cell lines

90 ed in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC) cell lines

91 levels of the oncogenic DeltaNp73 isoform in head and neck squamous cell carcinoma (HNSCC) cell lines

92 We modulated cortactin expression in head and neck squamous cell carcinoma (HNSCC) cell lines

93 We found that OPN is induced in head and neck squamous cell carcinoma (HNSCC) cell lines

94 he effects of the retinoid MX3350-1 on human head and neck squamous cell carcinoma (HNSCC) cell lines

95 gainst EGFR-expressing cell lines, including head and neck squamous cell carcinoma (HNSCC) cell lines

96 We examined NKG2D ligand expression in head and neck squamous cell carcinoma (HNSCC) cells and

97 Rac was activated in human head and neck squamous cell carcinoma (HNSCC) cells as e

98 rx metabolism enhanced cell killing of human head and neck squamous cell carcinoma (HNSCC) cells by a

99 we report studies of the in vivo invasion of head and neck squamous cell carcinoma (HNSCC) cells in r

100 e and TIC-like phenotypes in patient-derived head and neck squamous cell carcinoma (HNSCC) cells in v

101 Sema4D, the product of which is elevated in head and neck squamous cell carcinoma (HNSCC) cells, con

102 as been developed for metabolic profiling of head and neck squamous cell carcinoma (HNSCC) cells.

103 nvasion, migration and the CIC population in head and neck squamous cell carcinoma (HNSCC) cells.

104 Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a

105 ologic studies suggest that the incidence of head and neck squamous cell carcinoma (HNSCC) correlates

106 s epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy m

107 Head and neck squamous cell carcinoma (HNSCC) has a proc

108 Head and neck squamous cell carcinoma (HNSCC) has a vari

109 therapies, approximate 50% survival rate of head and neck squamous cell carcinoma (HNSCC) has had ma

110 reated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not be

111 ar survival rate in patients with late-stage head and neck squamous cell carcinoma (HNSCC) has not im

112 dence of human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) has rapidl

113 nts with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have bette

114 tribute to the initiation and progression of head and neck squamous cell carcinoma (HNSCC) have not b

115 Although the incidence of head and neck squamous cell carcinoma (HNSCC) in the Uni

116 Head and neck squamous cell carcinoma (HNSCC) includes e

117 Both PGE2 and BK stimulated head and neck squamous cell carcinoma (HNSCC) invasion v

118 Head and neck squamous cell carcinoma (HNSCC) is a commo

119 Human head and neck squamous cell carcinoma (HNSCC) is a highl

120 Head and neck squamous cell carcinoma (HNSCC) is a highl

121 Head and neck squamous cell carcinoma (HNSCC) is a leadi

122 Head and neck squamous cell carcinoma (HNSCC) is a leadi

123 Head and neck squamous cell carcinoma (HNSCC) is a very

124 Head and neck squamous cell carcinoma (HNSCC) is an aggr

125 Head and neck squamous cell carcinoma (HNSCC) is an aggr

126 Head and neck squamous cell carcinoma (HNSCC) is charact

127 Head and neck squamous cell carcinoma (HNSCC) is general

128 Head and neck squamous cell carcinoma (HNSCC) is one of

129 The unique characteristic of head and neck squamous cell carcinoma (HNSCC) is that lo

130 Head and neck squamous cell carcinoma (HNSCC) is the eig

131 Head and neck squamous cell carcinoma (HNSCC) is the mos

132 Head and neck squamous cell carcinoma (HNSCC) is the six

133 Head and neck squamous cell carcinoma (HNSCC) is the six

134 Head and neck squamous cell carcinoma (HNSCC) is the six

135 Head and neck squamous cell carcinoma (HNSCC) is the six

136 Head and neck squamous cell carcinoma (HNSCC) is the six

137 re compared for activity in protecting human head and neck squamous cell carcinoma (HNSCC) lines from

138 s frequently downregulated not only in human head and neck squamous cell carcinoma (HNSCC) malignant

139 ies have implicated a role for SDF-1alpha in head and neck squamous cell carcinoma (HNSCC) metastasis

140 To investigate how STAT3 activity in human head and neck squamous cell carcinoma (HNSCC) might alte

141 of therapy for patients with advanced stage head and neck squamous cell carcinoma (HNSCC) or recurre

142 h factor receptor (EGFR)-targeted therapy in head and neck squamous cell carcinoma (HNSCC) patients f

143 Head and neck squamous cell carcinoma (HNSCC) patients h

144 Most head and neck squamous cell carcinoma (HNSCC) patients p

145 of approximately 6,000 single cells from 18 head and neck squamous cell carcinoma (HNSCC) patients,

146 ance to chemotherapy and reduced survival of head and neck squamous cell carcinoma (HNSCC) patients.

147 get of rapamycin (mTOR) signaling network in head and neck squamous cell carcinoma (HNSCC) progressio

148 Head and neck squamous cell carcinoma (HNSCC) progressio

149 Head and neck squamous cell carcinoma (HNSCC) remains a

150 critical mediator of this pathway, Smad4, in head and neck squamous cell carcinoma (HNSCC) remains un

151 Head and neck squamous cell carcinoma (HNSCC) represents

152 isons of global miRNA expression profiles of head and neck squamous cell carcinoma (HNSCC) samples an

153 nt study, microarray expression profiling on head and neck squamous cell carcinoma (HNSCC) samples id

154 By comparing head and neck squamous cell carcinoma (HNSCC) samples wi

155 s from human papillomavirus-related (HPV(+)) head and neck squamous cell carcinoma (HNSCC) samples.

156 from several studies, including data from a Head and Neck Squamous Cell Carcinoma (HNSCC) study and

157 In this study, miRNA expression profiles of head and neck squamous cell carcinoma (HNSCC) tumor and

158 l cell line and expression data from primary head and neck squamous cell carcinoma (HNSCC) tumor tiss

159 we analyzed integrated data obtained from 19 head and neck squamous cell carcinoma (HNSCC) tumors and

160 es the invasive cell growth of p53-deficient head and neck squamous cell carcinoma (HNSCC) UM-SCC-1 c

161 e SELP analogs in a xenograft mouse model of head and neck squamous cell carcinoma (HNSCC) was shown

162 specific immune and metabolic phenotypes in head and neck squamous cell carcinoma (HNSCC) were asses

163 ceptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aber

164 Major weight loss is common in patients with head and neck squamous cell carcinoma (HNSCC) who underg

165 on factor RUNX2 is widely upregulated in the head and neck squamous cell carcinoma (HNSCC) with lymph

166 trategies are needed to improve treatment of head and neck squamous cell carcinoma (HNSCC), an aggres

167 papillomavirus (HPV) is an accepted cause of head and neck squamous cell carcinoma (HNSCC), and patie

168 is occurs in more than half of patients with head and neck squamous cell carcinoma (HNSCC), and these

169 For patients with locoregional advanced head and neck squamous cell carcinoma (HNSCC), concurren

170 Here, we show that in head and neck squamous cell carcinoma (HNSCC), CTGF prom

171 Atlas in October 2013 for 305 patients with head and neck squamous cell carcinoma (HNSCC), from 14 i

172 or gene is involved in the carcinogenesis of head and neck squamous cell carcinoma (HNSCC), the entir

173 e been the standard treatment modalities for head and neck squamous cell carcinoma (HNSCC), the integ

174 er exploited this synergistic combination in head and neck squamous cell carcinoma (HNSCC), up to 90%

175 ls of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), where AXL

176 r (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGF

177 is a common event in many cancers, including head and neck squamous cell carcinoma (HNSCC), where STA

178 n several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC), which exh

179 TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with muta

180 present study, we examined the role of human head and neck squamous cell carcinoma (HNSCC)-secreted S

181 tment efficacy, of anticancer drugs in human head and neck squamous cell carcinoma (HNSCC).

182 l role in epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC).

183 e role in various types of cancer, including head and neck squamous cell carcinoma (HNSCC).

184 ial to the development of novel treatment of head and neck squamous cell carcinoma (HNSCC).

185 e, we reveal a defective molecular switch in head and neck squamous cell carcinoma (HNSCC).

186 the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC).

187 the three most commonly amplified regions in head and neck squamous cell carcinoma (HNSCC).

188 potential role of hedgehog (Hh) signaling in head and neck squamous cell carcinoma (HNSCC).

189 ng is common in many malignancies, including head and neck squamous cell carcinoma (HNSCC).

190 and downstream targets, and TP53 genotype in head and neck squamous cell carcinoma (HNSCC).

191 enografts derived from 3 cell lines of human head and neck squamous cell carcinoma (HNSCC).

192 and usually fatal for patients with advanced head and neck squamous cell carcinoma (HNSCC).

193 inase as a novel target for the treatment of head and neck squamous cell carcinoma (HNSCC).

194 tion could effectively inhibit the growth of head and neck squamous cell carcinoma (HNSCC).

195 investigated TLR4 signaling effects on human head and neck squamous cell carcinoma (HNSCC).

196 ttle change in the survival of patients with head and neck squamous cell carcinoma (HNSCC).

197 l growth factor receptor (EGFR) is common in head and neck squamous cell carcinoma (HNSCC).

198 rk was to identify new molecular markers for head and neck squamous cell carcinoma (HNSCC).

199 CXCL5, in the proliferation and invasion of head and neck squamous cell carcinoma (HNSCC).

200 f the p16INK4A gene, is commonly observed in head and neck squamous cell carcinoma (HNSCC).

201 d together with the p53 family member p63 in head and neck squamous cell carcinoma (HNSCC).

202 rtant role in various cancers, including the head and neck squamous cell carcinoma (HNSCC).

203 n papillomavirus (HPV) detection and risk of head and neck squamous cell carcinoma (HNSCC).

204 adical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC).

205 Invasion is a hallmark of advanced head and neck squamous cell carcinoma (HNSCC).

206 tive chemotherapy of solid tumors, including head and neck squamous cell carcinoma (HNSCC).

207 tegies have been successfully implemented in head and neck squamous cell carcinoma (HNSCC).

208 velopment, establishment, and progression of head and neck squamous cell carcinoma (HNSCC).

209 inase inhibitors in unselected patients with head and neck squamous cell carcinoma (HNSCC).

210 ients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

211 variety of aggressive tumor types, including head and neck squamous cell carcinoma (HNSCC); however,

212 ctor receptor (EGFR) is found in over 80% of head and neck squamous cell carcinomas (HNSCC) and assoc

213 e ability of celecoxib to induce toxicity in head and neck squamous cell carcinomas (HNSCC) and explo

214 ssociated endothelial cells of patients with head and neck squamous cell carcinomas (HNSCC) as compar

215 cells are located in the invasive fronts of head and neck squamous cell carcinomas (HNSCC) close to

216 Head and neck squamous cell carcinomas (HNSCC) exhibitin

217 The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor th

218 nt and the appearance of secondary tumors in head and neck squamous cell carcinomas (HNSCC) have been

219 production of prostaglandin E(2) (PGE(2)) by head and neck squamous cell carcinomas (HNSCC) induce ty

220 Head and neck squamous cell carcinomas (HNSCC) is a comm

221 Head and neck squamous cell carcinomas (HNSCC) often met

222 ding of cancer, the 5-year survival rate for head and neck squamous cell carcinomas (HNSCC) patients

223 Combined treatment of advanced head and neck squamous cell carcinomas (HNSCC) with radi

224 sifiers of CIMP) in 344 bladder cancers, 346 head and neck squamous cell carcinomas (HNSCC), 146 non-

225 rtactin is associated with poor prognosis in head and neck squamous cell carcinomas (HNSCC), possibly

226 ns in serum or tumor tissue of patients with head and neck squamous cell carcinomas (HNSCC), suggesti

227 Head and neck squamous cell carcinomas (HNSCC), the majo

228 inhibitors of IKKbeta or EGFR is observed in head and neck squamous cell carcinomas (HNSCC).

229 have been reported to occur in 10% to 15% of head and neck squamous cell carcinomas (HNSCC).

230 erved in human papillomavirus (HPV)-positive head and neck squamous cell carcinomas (HNSCC).

231 matrix assembled by stromal fibroblasts from head and neck squamous cell carcinomas (HNSCC).

232 lay an important role in the pathobiology of head and neck squamous cell carcinomas (HNSCC).

233 ces cell death and inhibits tumorigenesis in head and neck squamous cell carcinomas (HNSCC).

234 EGFR is upregulated in the majority of head and neck squamous cell carcinomas (HNSCC).

235 The prognosis of head-and-neck squamous cell carcinoma (HNSCC) has not be

236 beta1) was frequently overexpressed in human head and neck squamous cell carcinomas (HNSCCs) and adja

237 Bcl-2 family member, occurs in a majority of head and neck squamous cell carcinomas (HNSCCs) and corr

238 Human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCCs) are dead

239 Head and neck squamous cell carcinomas (HNSCCs) are high

240 Head and neck squamous cell carcinomas (HNSCCs) are refr

241 highly expressed in cell lines derived from head and neck squamous cell carcinomas (HNSCCs) at both

242 Only a subset of patients with head and neck squamous cell carcinomas (HNSCCs) benefit

243 16, are associated with approximately 20% of head and neck squamous cell carcinomas (HNSCCs) in the g

244 However, more recent studies of head and neck squamous cell carcinomas (HNSCCs) suggest

245 ay a role in the pathogenesis of a subset of head and neck squamous cell carcinomas (HNSCCs), particu

246 To identify miRNAs associated with head and neck squamous cell carcinomas (HNSCCs), we anal

247 erse-phase protein array data (n = 212) from head and neck squamous cell carcinomas (HNSCCs).

248 ation of Brca1 begins at the early stages of head and neck squamous cell carcinomas (HNSCCs).

249 ve been independently detected in subsets of head and neck squamous cell carcinomas (HNSCCs).

250 ve factor in over 90% of cervical and 25% of head and neck squamous cell carcinomas (HNSCCs).

251 nd prosurvival roles, respectively, in human head and neck squamous cell carcinomas (HNSCCs).

252 , more than 90% of head and neck cancers are head and neck squamous cell carcinomas (HNSCCs).

253 /TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas (HNSCCs).

254 Human papillomavirus-associated head and neck squamous cell carcinomas (HPV-HNSCC) origi

255 Analysis of 47 lung and head and neck squamous cell carcinomas identified a case

256 esophageal squamous cell carcinomas, and 270 head and neck squamous cell carcinomas (identified from

257 established as a risk factor for developing head and neck squamous cell carcinoma, independent of to

258 Human head and neck squamous cell carcinoma is a solid tumor m

259 nt of lymph node metastasis in patients with head and neck squamous cell carcinoma is not accurate en

260 scan of the neck in locoregionally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after co

261 In head and neck squamous cell carcinoma, local failure aft

262 ending toxin; CSC, cancer stem cells; HNSCC, head and neck squamous cell carcinoma; MAb, monoclonal a

263 in 1 trial of patients with locally advanced head and neck squamous cell carcinoma (median survival,

264 ated in multiple aggressive cancers, such as head and neck squamous cell carcinoma, melanoma and panc

265 nal cell carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, thyroid

266 of cancer stem cells in the pathobiology of head and neck squamous cell carcinomas might have a prof

267 ancer models driven by MMTV-Wnt1 and a human head and neck squamous cell carcinoma model (HN30).

268 ith OPSCC and patients with nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC).

269 ith OPSCC and patients with nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC).

270 ell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, or gastro-oesopha

271 present in tumors or the peripheral blood of head and neck squamous cell carcinoma patients co-expres

272 e in primary human tumor tissue samples from head and neck squamous cell carcinoma patients.

273 table safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated

274 CaMKII-mediated cytoskeleton function and in head and neck squamous cell carcinoma progression.

275 approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to plat

276 y (ICT) in the treatment of locally advanced head and neck squamous cell carcinoma remains controvers

277 gFuge to RNA-seq cohorts of 177 lung and 279 head and neck squamous cell carcinoma samples from the C

278 gene sets relative to training data sets of head and neck squamous cell carcinoma samples, one inclu

279 In an orthotopic murine model of head and neck squamous cell carcinoma (SCC VII/SF) we st

280 ts of Rap1GAP on invasion and progression of head and neck squamous cell carcinoma (SCC) and the role

281 Carcinogens associated with head and neck squamous cell carcinoma (SCC) genesis shou

282 orming growth factor (TGF)-beta signaling in head and neck squamous cell carcinoma (SCC) is not yet f

283 he associations between dietary patterns and head and neck squamous cell carcinoma (SCC) or whether t

284 Tumor RF ablation therapy was performed on head and neck squamous cell carcinoma (SCC) xenograft tu

285 Here, we show that PKCalpha promotes head and neck squamous cell carcinoma (SCCHN) by a feed-

286 We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which cor

287 mal differentiation and cause anogenital and head and neck squamous cell carcinomas (SCCs).

288 A retrospective evaluation of head and neck squamous cell carcinomas showed heterogene

289 is the first report of elevated PKC iota in head and neck squamous cell carcinoma that may have sign

290 t that GSPs may be a promising candidate for head and neck squamous cell carcinoma therapy.

291 nd DUSP1 mRNA and protein decreased in human head and neck squamous cell carcinoma tissues compared w

292 ignificant promoter demethylation in primary head and neck squamous cell carcinoma tissues.

293 gnant biopsy specimens from 23 patients with head and neck squamous cell carcinoma to characterize th

294 rived from autologous primary and metastatic head and neck squamous cell carcinoma, to investigate th

295 and diagnostic CT images in 20 patients with head and neck squamous cell carcinoma treated with curat

296 In the first experiment, a single human head-and-neck squamous cell carcinoma tumor was grown in

297 ipts were detected using RNA-Seq analysis in head-and-neck squamous cell carcinoma, uterine endometri

298 In this study, 16 patients with head and neck squamous cell carcinoma were enrolled (med

299 Treatment of head and neck squamous cell carcinomas with radiotherapy

300 Eighty mice with patient-derived head and neck squamous cell carcinomas xenografts, SCCNi